The mosaic of schizophrenia: Has the time arrived to monitor the illness with biomarkers?

Clinical Biochemistry

Volumn 41, Issue 6, 2008, Pages 353-354

  Strous, Rael D ^a,b   Shoenfeld, Yehuda ^b,c  

^a BEER YAAKOV MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; BIOLOGICAL MARKER; CRYOGLOBULIN; CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TYPE III CRYOGLOBULIN; UNCLASSIFIED DRUG;

AUTOIMMUNITY; BRAIN DYSFUNCTION; COGNITIVE DEFECT; DEPRESSION; DISEASE PREDISPOSITION; DISEASE SEVERITY; EDITORIAL; ENVIRONMENTAL FACTOR; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFECTION SENSITIVITY; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA; TH1 CELL; TH2 CELL; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANIMALS; BIOLOGICAL MARKERS; CRYOGLOBULINS; HUMANS; PSYCHONEUROIMMUNOLOGY; SCHIZOPHRENIA;

EID: 40849111368     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.12.004     Document Type: Editorial

References (19)

1. Freedman R. Schizophrenia. N Engl J Med 349 (2003) 1738-1749
2. Strous R.D., and Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun 27 (2006) 71-80
3. Rosenberg S.D., Goodman L.A., Osher F.C., et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 91 (2001) 31-37
4. Dinwiddie S.H., Shicker L., and Newman T. Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry 160 (2003) 172-174
5. Nakamura Y., Koh M., Miyoshi E., et al. High prevalence of the hepatitis C virus infection among the inpatients of schizophrenia and psychoactive substance abuse in Japan. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 591-597
6. Freudenreich O., Gandhi R.T., Walsh J.P., Henderson D.C., and Goff D.C. Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort. Psychosomatics 48 (2007) 405-411
7. Teplizki-Amital H., Sela B., and Shoenfeld Y. Autoantibodies to brain polynucleotides in patients with schizophrenia. Immunol Res 11 (1992) 66-73
8. Irwin M.R., and Miller A.H. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 21 (2007) 374-383
9. Huerta P.T., Kowal C., DeGiorgio L.A., Volpe B.T., and Diamond B. Immunity and behavior: antibodies alter emotion. Proc Natl Acad Sci U S A 103 (2006) 678-683
10. Lapteva L., Nowak M., Yarboro C.H., et al. Anti-N-methyl-d-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 54 (2006) 2505-2514
11. Katzav A., Solodeev I., Brodsky O., et al. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum 56 (2007) 938-948
12. Strous R.D., and Shoenfeld Y. Revisiting old ghosts: prenatal viral exposure and schizophrenia. Isr Med Assoc J 7 (2005) 43-45
13. Shoenfeld Y., and Isenberg D.A. The mosaic of autoimmunity. Immunol Today 10 (1989) 123-126
14. Brickman C.M., and Shoenfeld Y. The mosaic of autoimmunity. Scand J Clin Lab Invest 61 (2001) 3-15
15. Amital H., Gershwin M.E., and Shoenfeld Y. Editorial: reshaping the mosaic of autoimmunity. Semin Arthritis Rheum 35 (2006) 341-342
16. Skurkovich B., and Skurkovich S. Anti-interferon-gamma antibodies in the treatment of autoimmune diseases. Curr Opin Mol Ther 5 (2003) 52-57
17. Caruso A., and Turano A. Natural antibodies to interferon-gamma. Biotherapy 10 (1997) 29-37
18. Riedel M., Strassnig M., Schwarz M.J., and Muller N. COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date. CNS Drugs 19 (2005) 805-819
19. Brekke O.H., and Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2 (2003) 52-62